Key Target Markets Prolacta serves Level 3&4 NICUs with 100% human milk-based products, trusted by over half of these units. Sales opportunities exist in hospitals expanding NICU capacity or seeking standard-of-care improvements to reduce premature infant complications and stay costs.

Clinical Education Recent appointment of a director of clinical education and professional development signals a focus on clinician engagement. Leverage opportunities to partner on training programs, case studies, and CME-aligned content to drive adoption of Exclusive Human Milk Diet products.

Surgical Niche Surgifort, the FDA-approved human milk-based fortifier for term infants recovering from gastroschisis surgery, presents a cross-sell opportunity to NICUs and pediatric surgical centers managing post-surgical neonates.

Financial Position Revenue scale ($100M-$250M) and ongoing leadership hires (CFO in 2022) indicate growing steadiness and investor-facing credibility. Target procurement and finance stakeholders for contract optimization, volume-based pricing, and value-based purchasing discussions.

Clinical Evidence 30+ peer-reviewed studies support shorter NICU stays and better outcomes with human milk-based formulas. Use these data points to build ROI-driven proposals with hospital administrators and finance teams highlighting total cost reduction.